John Maddox Prize 2021

Nominations for the John Maddox Prize 2021 have just opened. Now in its tenth year, the prize is the initiative of Sense about Science and Nature. The John Maddox Prize recognises the work of an individual to promote sound science and evidence on a matter of public interest, facing difficulty or hostility in doing so. […]

Read More… from John Maddox Prize 2021

First Patient in Historic First-in-Human Clinical Trial for Glioblastoma

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, has announced the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy (SDT), a non invasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop […]

Read More… from First Patient in Historic First-in-Human Clinical Trial for Glioblastoma

First Patient in Historic First-in-Human Clinical Trial for Glioblastoma

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, has announced the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy (SDT), a non invasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop […]

Read More… from First Patient in Historic First-in-Human Clinical Trial for Glioblastoma

Pandemic mealtimes of seriously ill or disabled children

Pandemic mealtimes of seriously ill or disabled children: Almost nine in 10 parents with seriously ill or disabled children feel the pandemic has negatively impacted their mealtimes. A study of 1,142 parents with disabled children found 48 per cent also said their youngsters’ different needs has stopped them coming together as a family. And 58 […]

Read More… from Pandemic mealtimes of seriously ill or disabled children

Pandemic mealtimes of seriously ill or disabled children

Pandemic mealtimes of seriously ill or disabled children: Almost nine in 10 parents with seriously ill or disabled children feel the pandemic has negatively impacted their mealtimes. A study of 1,142 parents with disabled children found 48 per cent also said their youngsters’ different needs has stopped them coming together as a family. And 58 […]

Read More… from Pandemic mealtimes of seriously ill or disabled children

ProFound AI May Reduce Interval Breast Cancer Rates

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates: Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions. NASHUA, N.H. – March 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), […]

Read More… from ProFound AI May Reduce Interval Breast Cancer Rates

ProFound AI May Reduce Interval Breast Cancer Rates

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates: Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions. NASHUA, N.H. – March 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), […]

Read More… from ProFound AI May Reduce Interval Breast Cancer Rates

New Huntington’s disease trial

Aberdeen has recruited the first UK patient for a new trial investigating pridopidine, an oral drug for the treatment of Huntington’s disease. The PROOF-HD study, sponsored by Prilenia Therapeutics, will enrol up to 480 people with early-stage Huntington’s at approximately 60 sites across the US, Canada, and Europe. Huntington’s disease – often known as HD […]

Read More… from New Huntington’s disease trial

New Huntington’s disease trial

Aberdeen has recruited the first UK patient for a new trial investigating pridopidine, an oral drug for the treatment of Huntington’s disease. The PROOF-HD study, sponsored by Prilenia Therapeutics, will enrol up to 480 people with early-stage Huntington’s at approximately 60 sites across the US, Canada, and Europe. Huntington’s disease – often known as HD […]

Read More… from New Huntington’s disease trial